Ontology highlight
ABSTRACT:
SUBMITTER: Torkamand F
PROVIDER: S-EPMC6872472 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
Torkamand Farbod F Mirjavadi Seyed Javad SJ Khatami Fatemeh F Guitynavard Fateme F Aghamir Seyed Mohammad Kazem SMK
American journal of clinical and experimental urology 20191025 5
Botulinum toxins were primary suggested for the neurogenic lower urinary tract dysfunction (LUTD) treatment about thirty years ago. The application of BTX-A in LUTD have just developed and the approval of BTX-A injection confirmed in for patients with both overactive bladders (OAB) and neurogenic detrusor overactivity (NDO). Actually the BTX-A medication in interstitial cystitis/bladder pain syndrome (IC/BPS) is not licensed, but there is under consideration. Despite BTX-A is recommended to trea ...[more]